On May 11, Jiudian Pharmaceutical announced that the company recently received the "Notice of Approval of Supplementary Drug Application" issued by the State Drug Administration. The main content of this application is to change the drug marketing authorization holder of Dexketoprofen Tromethamine Tablets from Hunan Nona Pharmaceutical Technology Co., Ltd. to the company, and the production site remains unchanged. This drug is a non-steroidal anti-inflammatory drug and is suitable for the treatment of a variety of mild to moderate pain.

According to Moentropy data, the total sales of Dexketoprofen Tromethamine Tablets in hospitals and pharmacies nationwide will be 42.01 million yuan in 2021, 55.99 million yuan in 2022, and 41.07 million yuan in 2023. The approval notice for the supplementary drug application obtained this time will further enrich the company's product pipeline and have positive significance for optimizing the product structure.

In the first quarter of 2025, Jiudian Pharmaceutical achieved revenue of 696 million yuan and net profit attributable to shareholders of the parent company of 126 million yuan.

https://finance.eastmoney.com/a/202505113401339430.html